embolic protection product line. Additional charges related to severance
and clinical trial closeout costs were recorded in the first fiscal
quarter of 2008, as set forth in the reconciliation. In addition, the
Company is excluding the impact of the acceleration of vesting of the
stock awards from the first quarter results due to the "Change in Control"
as defined in the Company's equity compensation plan on August 30, 2007
when Ramius Capital Group, L.L.C. and its affiliates acquired more than 20
percent of the Company's outstanding common stock.
These non-GAAP measures will provide investors and management with an
alternative method for assessing Kensey Nash's operating results in a
manner consistent with the presentation prior to the discontinuance of our
embolic protection division and the accelerated vesting of stock awards.
Further, these non-GAAP results are one of the primary indicators
management uses for planning and forecasting in future periods. The
presentation of this additional information should not be considered in
isolation or as a substitute for results prepared in accordance with
accounting principles generally accepted in the United States.
| SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved |